Vericel (VCEL) 10-Q 10 May 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2023	Apr. 30, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-35280
Entity Registrant Name	VERICEL CORPORATION
Entity Incorporation, State or Country Code	MI
Entity Tax Identification Number	94-3096597
Entity Address, Address Line One	64 Sidney Street
Entity Address, City or Town	Cambridge
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02139
City Area Code	617
Local Phone Number	588-5555
Title of 12(b) Security	Common Stock (No par value)
Trading Symbol	VCEL
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		47,564,919
Entity Central Index Key	0000887359
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 61,834	$ 51,067
Short-term investments	57,442	68,471
Accounts receivable (net of allowance for doubtful accounts of $47 and $47, respectively)	38,359	46,539
Inventory	15,370	15,986
Other current assets	4,540	4,803
Total current assets	177,545	186,866
Property and equipment, net	18,197	15,837
Intangible assets, net	7,344	7,500
Right-of-use assets	40,851	41,535
Long-term investments	19,910	19,962
Other long-term assets	1,249	1,303
Total assets	265,096	273,003
Current liabilities:
Accounts payable	11,125	16,930
Accrued expenses	13,111	16,190
Current portion of operating lease liabilities	4,497	4,302
Other current liabilities	20	41
Total current liabilities	28,753	37,463
Operating lease liabilities	42,365	43,268
Total liabilities	71,118	80,731
COMMITMENTS AND CONTINGENCIES (Note 12)
Shareholders’ equity:
Common stock, no par value; shares authorized — 75,000; shares issued and outstanding 47,507 and 47,253, respectively	602,104	593,245
Accumulated other comprehensive loss	(636)	(978)
Accumulated deficit	(407,490)	(399,995)
Total shareholders’ equity	193,978	192,272
Total liabilities and shareholders’ equity	$ 265,096	$ 273,003

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 47	$ 47
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	47,507,000	47,253,000
Ending balance (in shares)	47,507,000	47,253,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenue, Product and Service [Extensible List]	Product [Member]
Product sales, net	$ 41,017	$ 35,852
Other revenue	0	222
Total revenue	$ 41,017	36,074
Cost, Product and Service [Extensible List]	Product [Member]
Cost of product sales	$ 14,497	12,622
Gross profit	26,520	23,452
Research and development	5,212	4,860
Selling, general and administrative	29,485	25,865
Total operating expenses	34,697	30,725
Loss from operations	(8,177)	(7,273)
Other income (expense):
Interest income	839	88
Interest expense	(145)	(18)
Other (expense) income	(12)	112
Total other income	682	182
Net loss	$ (7,495)	$ (7,091)
Net loss per common share:
Basic (in USD per share)	$ (0.16)	$ (0.15)
Diluted (in USD per share)	$ (0.16)	$ (0.15)
Weighted-average common shares outstanding:
Basic (in shares)	47,387	46,985
Diluted (in shares)	47,387	46,985

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement of Comprehensive Income [Abstract]
Net loss	$ (7,495)	$ (7,091)
Other comprehensive loss:
Unrealized gain (loss) on investments	342	(459)
Comprehensive loss	$ (7,153)	$ (7,550)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Accumulated Other Comprehensive Gain (Loss)	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021		46,880
Beginning balance at Dec. 31, 2021	$ 170,462	$ 553,902	$ (154)	$ (383,286)
Increase (Decrease) in Shareholders' Equity
Net loss	(7,091)			(7,091)
Stock-based compensation expense	9,531	$ 9,531
Stock option exercises (in shares)		125
Stock option exercises	1,155	$ 1,155
Shares issued under the Employee Stock Purchase Plan (in shares)		9
Shares issued under the Employee Stock Purchase Plan	310	$ 310
Issuance of stock for restricted stock unit vesting (in shares)		108
Restricted stock withheld for employee tax remittance (in shares)		(41)
Restricted stock withheld for employee tax remittance	(1,423)	$ (1,423)
Unrealized gain (loss) on investment	(459)		(459)
Ending balance (in shares) at Mar. 31, 2022		47,081
Ending balance at Mar. 31, 2022	$ 172,485	$ 563,475	(613)	(390,377)
Beginning balance (in shares) at Dec. 31, 2022	47,253	47,253
Beginning balance at Dec. 31, 2022	$ 192,272	$ 593,245	(978)	(399,995)
Increase (Decrease) in Shareholders' Equity
Net loss	(7,495)			(7,495)
Stock-based compensation expense	8,731	$ 8,731
Stock option exercises (in shares)		132
Stock option exercises	2,009	$ 2,009
Shares issued under the Employee Stock Purchase Plan (in shares)		11
Shares issued under the Employee Stock Purchase Plan	216	$ 216
Issuance of stock for restricted stock unit vesting (in shares)		183
Restricted stock withheld for employee tax remittance (in shares)		(72)
Restricted stock withheld for employee tax remittance	(2,097)	$ (2,097)
Unrealized gain (loss) on investment	$ 342		342
Ending balance (in shares) at Mar. 31, 2023	47,507	47,507
Ending balance at Mar. 31, 2023	$ 193,978	$ 602,104	$ (636)	$ (407,490)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating activities:
Net loss	$ (7,495)	$ (7,091)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation and amortization expense	1,158	873
Stock-based compensation expense	8,731	9,531
Amortization of premiums and discounts on marketable securities	(290)	194
Amortization of debt issuance costs	54	0
Non-cash lease costs	1,112	1,076
Other	12	4
Changes in operating assets and liabilities:
Inventory	616	(1,004)
Accounts receivable	8,180	5,582
Other current assets	263	(847)
Accounts payable	(274)	(219)
Accrued expenses	(3,079)	(3,734)
Operating lease liabilities	(1,128)	(897)
Net cash provided by operating activities	7,860	3,468
Investing activities:
Purchases of investments	(9,787)	(12,629)
Sales and maturities of investments	21,500	5,041
Expenditures for property and equipment	(1,413)	(3,081)
Purchases of intangible assets	(7,500)	0
Net cash provided by (used in) investing activities	2,800	(10,669)
Financing activities:
Net proceeds from common stock issuance	2,225	1,465
Payments on employee’s behalf for taxes related to vesting of restricted stock unit awards	(2,097)	(943)
Other	(21)	(19)
Net cash provided by financing activities	107	503
Net increase (decrease) in cash, cash equivalents, and restricted cash	10,767	(6,698)
Cash, cash equivalents, and restricted cash at beginning of period	51,067	68,541
Cash, cash equivalents, and restricted cash at end of period	61,834	61,843
Supplemental disclosure of cash flow information:
Right-of-use asset and lease liability recognized	419	0
Additions to property and equipment included in accounts payable	2,282	317
Restricted stock held for employee tax remittance included in accounts payable	0	480
Reconciliation of amounts within the condensed consolidated balance sheets:
Cash and cash equivalents	61,834	55,659
Restricted cash	0	6,184
Total cash, cash equivalents, and restricted cash at end of period	$ 61,834	$ 61,843

Organization

Organization	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization Vericel Corporation, a Michigan corporation (together with its consolidated subsidiaries referred to herein as the Company, or Vericel), was incorporated in March 1989 and began employee-based operations in 1991. The Company is a fully-integrated, commercial-stage biopharmaceutical company and is a leader in advanced therapies for the sports medicine and severe burn care markets. Vericel currently markets three commercial-stage products in the U.S., MACI ® , Epicel ® and NexoBrid ® . MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area (“TBSA”). The Company also holds an exclusive license from MediWound Ltd. (“MediWound”) to commercialize NexoBrid (anacaulase-bcdb) in North America. On December 28, 2022, the U.S. Food and Drug Administration (“FDA”) approved a Biologics License Application (“BLA”) for NexoBrid, granting a license for commercial use in the U.S. NexoBrid is a topically-administered biological product containing proteolytic enzymes and is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns. The Company operates its business primarily in the U.S. in one reportable segment - the research, product development, manufacture and distribution of cellular therapies and specialty biologics for use in the treatment of specific diseases. The Company is subject to risks common to companies in the life sciences industry including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with FDA regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies. COVID-19 In March 2020, the World Health Organization declared the spread of a novel strain of coronavirus (“COVID-19”) to be a pandemic, which contributed to an economic downturn on a global scale, as well as significant volatility in the financial markets. At the time of the pandemic’s inception, and at times throughout its duration, there was significant volatility in the Company’s results of operations on a quarterly basis due to the widespread and periodic cancellation or delay of elective MACI surgical procedures throughout the U.S., staffing shortages and the Company’s ability to access customers. Based on declining COVID-related statistics, the U.S. Department of Health and Human Services has announced that the federal Public Health Emergency for COVID-19 is set to expire at the end of the day on May 11, 2023. Although at this juncture the pandemic’s effects on the Company’s business and results of operations have moderated, should a resurgence of COVID-19 occur it could result in additional disruptions that could impact the Company’s business and operations in the future, including intermittent restrictions on the ability of Company personnel to travel and access customers for selling, marketing, training, case support and product development feedback, delays in approvals by regulatory bodies, delays in product development efforts, and additional government requirements or other incremental mitigation efforts that may further impact its capacity to manufacture, sell and support the use of its products. The War in Ukraine The ongoing war between Russia and Ukraine and the related sanctions and other penalties imposed by countries across the globe against Russia are continuing to create substantial uncertainty in the global economy and have contributed to heightened inflation and supply chain disruptions. While the Company does not have operations in Russia or Ukraine and does not have exposure to distributors, or third-party service providers in Russia or Ukraine, it is unable to predict the ultimate impact that these actions will have on the global economy or on its financial condition, results of operations, and cash flows as of the date of these condensed consolidated financial statements. Liquidity The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of March 31, 2023, the Company had an accumulated deficit of $407.5 million and had a net loss of $7.5 million during the three months ended March 31, 2023. The Company had cash and cash equivalents of $61.8 million and investments of $77.4 million as of March 31, 2023. The Company expects that cash from the sales of its products and existing cash, cash equivalents, investments, and available borrowing capacity will be sufficient to support the Company’s current operations through at least 12 months from the issuance of these condensed consolidated financial statements. If revenues decline for a sustained period, the Company may need to access additional capital; however, the Company may not be able to obtain additional financing on acceptable terms or at all. The terms of any additional financing may adversely affect the holdings or the rights of the Company’s shareholders. Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and investments in marketable debt securities. The Company may maintain deposits in financial institutions in excess of the insurance coverage offered by the Federal Deposit Insurance Corporation (“FDIC”), the loss of which could have a negative effect on our operations and liquidity. The Company is closely monitoring ongoing events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally. The Company believes that it is not exposed to significant credit risk as its deposits, including cash and cash equivalents, are held at multiple high credit quality financial institutions. The Company has not experienced any losses on these deposits; however no assurances can be provided that there will not be losses experienced in the future. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated based on the fact that many of these securities are either government-backed or of high credit rating.

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements of Vericel are unaudited and have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expenses. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expenses. The condensed consolidated balance sheet as of December 31, 2022 has been derived from the audited consolidated financial statements at that date, but does not include all the information and notes required by U.S. GAAP for complete financial statements. These c ondensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on February 23, 2023 (“Annual Report”). Recent Accounting Pronouncements No new accounting standards were adopted during the three months ended March 31, 2023. The Company considers the applicability and impact of any recent Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). Based on the assessment, the ASUs were determined to be either not applicable or are expected to have minimal impact on the Company’s condensed consolidated financial statements.

Revenue

Revenue	3 Months Ended
	Mar. 31, 2023
Risks and Uncertainties [Abstract]
Revenue	Revenue Revenue Recognition and Product Sales, Net The Company recognizes product revenue from sales of MACI biopsy kits, MACI implants, Epicel grafts and NexoBrid following the five-step model in Accounting Standards Codification 606, Revenue Recognition. MACI Biopsy Kits MACI biopsy kits are sold directly to hospitals and ambulatory surgical centers based on contracted rates in an approved contract or sales order. The Company recognizes MACI kit revenue upon delivery of the biopsy kit, at which time the customer (the facility) is in control of the kit. The kit is used by the doctor to provide a sample of cartilage tissue to the Company, which can later be used to manufacture a MACI implant. The ordering of the kit does not obligate the Company to manufacture an implant nor does the receipt of the cartilage tissue by the Company from the customer following biopsy. The customer’s order of an implant is separate from the process of ordering the biopsy kit. Therefore, the sale of the biopsy kit and any subsequent sale of an implant are distinct contracts and are accounted for separately. MACI Implants The Company contracts with two specialty pharmacies, Orsini Pharmaceutical Services, Inc. (“Orsini”) and AllCare Plus Pharmacy, Inc. (“AllCare”) to distribute MACI in a manner in which the Company retains the credit and collection risk from the end customer. The Company pays both specialty pharmacies a fee for each patient to whom MACI is dispensed. Both Orsini and AllCare perform collection activities to collect payment from customers. The Company engages a third party to provide services in connection with a patient support program to manage patient cases and to ensure complete and correct billing information is provided to the insurers and hospitals. In addition, the Company also sells MACI directly to DMS Pharmaceutical Group, Inc. (“DMS”) for patients treated at military treatment facilities. The sales directly to DMS are made at a contracted rate. Prior authorization and confirmation of coverage level by the patient’s private insurance plan, hospital or government payer is a prerequisite to the shipment of product to a patient. The Company recognizes product revenue from sales of all MACI implants upon delivery at which time the customer obtains control of the implant and the claim is billable. The total consideration that the Company expects to collect in exchange for MACI implants (the “Transaction Price”) may be fixed or variable. Direct sales to hospitals or distributors are recorded at a contracted price, and there are typically no forms of variable consideration. When the Company sells MACI the patient is responsible for payment; however, the Company is typically reimbursed by a third-party insurer or government payer, subject to a patient co-pay amount. Reimbursements from third-party insurers and government payers vary by patient and payer and are based on either contracted rates, publicly available rates, fee schedules or past payer precedents. Net product revenue is recognized net of estimated contractual allowances, which considers historical collection experience from both the payer and patient, denial rates and the terms of the Company’s contractual arrangements. The Company estimates expected collections for these transactions using the portfolio approach. The Company records a reduction to revenue at the time of sale for its estimate of the amount of consideration that will not be collected. In addition, potential credit risk exposure has been evaluated for the Company’s accounts receivable in accordance with ASC 326, Financial Instruments - Credit Losses . The Company assesses risk and determines a loss percentage by pooling accounts receivable based on similar risk characteristics. The loss percentage is calculated through the use of forecasts that are based on current and historical economic and financial information. This loss percentage was applied to the accounts receivables as of March 31, 2023. The total allowance for uncollectible consideration as of March 31, 2023 and December 31, 2022 was $7.1 million and $6.1 million, respectively. Changes to the estimate of the amount of consideration that will not be collected could have a material impact on the revenue recognized. A 50 basis points change to the estimated uncollectible percentage could result in an approximately $0.3 million decrease or increase in the revenue recognized for the three months ended March 31, 2023. Changes in estimates of the Transaction Price are recorded through revenue in the period in which such change occurs. Changes in estimates related to prior periods are shown in the Revenue by Product and Customer table below and relate primarily to changes in the initial expected reimbursement or collection expectation upon completion of the billing claims process for MACI implants that occurred in a prior year. Epicel The Company sells Epicel directly to hospitals and burn centers based on contracted rates stated in an approved contract or purchase order. Similar to MACI, there is no obligation to manufacture Epicel grafts upon receipt of a skin biopsy, and Vericel has no contractual right to receive payment until the product is delivered to the hospital. The Company recognizes product revenue from sales of Epicel upon delivery to the hospital, at which time the customer is in control of the Epicel grafts and the claim is billable to the hospital. NexoBrid The Company entered into exclusive license and supply agreements with MediWound in May 2019, pursuant to which MediWound will manufacture and supply NexoBrid on a unit price basis, which may be increased pursuant to the terms of the agreements. Additionally, beginning in 2020 the U.S. Biomedical Advanced Research and Development Authority (“BARDA”) procured quantities of NexoBrid from MediWound, for use as a medical countermeasure in the event of a mass casualty emergency in the U.S. involving thermal burns. The initial, quarterly, procurement of NexoBrid by BARDA under its agreement with MediWound completed during the third quarter of 2022. The Company recognized revenue based on a percentage of gross profits for sales of NexoBrid to BARDA upon delivery, at which time BARDA was in control of the product. As of March 31, 2023, the Company did not hold a direct contract or distribution agreement with BARDA, or take title to the product procured by BARDA. On May 9, 2023, MediWound announced BARDA’s award of additional funding under the parties’ existing agreement, $3 million of which will support the replacement of NexoBrid, previously procured for emergency response preparedness, which has since expired. Pursuant to the terms of the Company’s license agreement with MediWound, the Company would recognize revenue based on a percentage of gross profits, minus a percentage of net sales, on any sales of NexoBrid directly to BARDA upon delivery, pursuant to this additional award. Additionally, on December 28, 2022, the FDA approved a BLA for NexoBrid, granting a license for commercial use in the U.S. NexoBrid is a topically-administered biological product containing proteolytic enzymes and is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns. Revenue by Product and Customer The following table and descriptions below show the products from which the Company generated its revenue for the periods indicated: Three Months Ended March 31, Revenue by product (in thousands) 2023 2022 MACI implants and kits Implants based on contracted rate sold through a specialty pharmacy (a) $ 22,698 $ 15,190 Implants subject to third party reimbursement sold through a specialty pharmacy (b) 3,485 3,369 Implants sold direct based on contracted rates (c) 6,919 5,634 Implants sold direct subject to third-party reimbursement (d) 501 861 Biopsy kits - direct bill 535 522 Change in estimates related to prior periods (e) 52 419 Total MACI implants and kits 34,190 25,995 Epicel Direct bill (hospital) 6,827 9,857 NexoBrid revenue (f) — 222 Total revenue $ 41,017 $ 36,074 (a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts. (b) Represents implants sold through Orsini and AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer, and are subject to third-party reimbursement. The amount of reimbursement is established based on publicly available rates, fee schedules or past payer precedents. (c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS. (d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider. (e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare and relate to changes to the initial expected reimbursement or collection expectations upon completion of the billing claims process. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period. (f) Represents revenue based on a percentage of gross profits for sales of NexoBrid to BARDA, pursuant to the license agreement between the Company and MediWound (see Note 11).

Selected Balance Sheet Componen

Selected Balance Sheet Components	3 Months Ended
	Mar. 31, 2023
Balance Sheet Related Disclosures [Abstract]
Selected Balance Sheet Components	Selected Balance Sheet Components Inventory Inventory consisted of the following: (In thousands) March 31, 2023 December 31, 2022 Raw materials $ 14,264 $ 15,101 Work-in-process 1,043 832 Finished goods 63 53 Total inventory $ 15,370 $ 15,986 Property and Equipment Property and Equipment, net consisted of the following: (In thousands) March 31, 2023 December 31, 2022 Machinery and equipment $ 5,212 $ 5,041 Furniture, fixtures and office equipment 1,710 1,710 Computer equipment and software 8,208 8,224 Leasehold improvements 14,120 13,689 Construction in process 8,121 5,438 Financing right-of-use lease 28 37 Total property and equipment, gross 37,399 34,139 Less accumulated depreciation (19,202) (18,302) Total property and equipment, net $ 18,197 $ 15,837 Depreciation expense for the three months ended March 31, 2023 and 2022 was $1.0 million and $0.9 million, respectively. Intangible Assets Intangible assets, net consisted of the following: March 31, 2023 December 31, 2022 (In thousands) Useful Live (in years) Amortization Method Cost Accumulated Amortization Net Cost Accumulated Amortization Net NexoBrid license 12 Straight-line $ 7,500 $ (156) $ 7,344 $ 7,500 $ — $ 7,500 Amortization expense for the three months ended March 31, 2023 was $0.2 million. Future amortization expense of intangible assets as of March 31, 2023 is estimated to be as follows: (In thousands) Amount Remainder of 2023 $ 469 2024 625 2025 625 2026 625 2027 625 Thereafter 4,375 Total $ 7,344 Accrued Expenses Accrued Expenses consisted of the following: (In thousands) March 31, 2023 December 31, 2022 Bonus related compensation $ 3,588 $ 7,132 Employee related accruals 2,739 3,101 Insurance reimbursement-related liabilities 5,769 5,030 Other accrued expenses 1,015 927 Total accrued expenses $ 13,111 $ 16,190

Leases

Leases	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Leases	Leases The Company leases facilities in Ann Arbor, Michigan and Cambridge, Massachusetts. The Ann Arbor facility includes office space, and the Cambridge facilities include clean rooms, laboratories for MACI and Epicel manufacturing, and office space. The Company also leases offsite warehouse space, and other computer-related equipment. With respect to the Ann Arbor facility, in March 2023, the Company entered into an amendment to that lease extending its term until April 30, 2025. Monthly contractual payments are expected to range from $17,000 to $18,000. On January 28, 2022, the Company entered into a lease agreement (the “Burlington Lease”) to lease approximately 126,000 square feet of to-be-constructed manufacturing, laboratory and office space in Burlington, Massachusetts (the “Premises”). Once constructed, the Premises will serve as the Company’s new corporate headquarters and primary manufacturing facility. The term of the Burlington Lease is currently expected to begin mid-year 2023 (the “Commencement Date”). The Company’s obligation to pay rent for the Premises will begin on the earlier of: 13 months from the Commencement Date; or the date on which the Company first occupies the Premises to conduct operations (the “Rent Commencement Date”). The initial term of the Lease is 144 months following the Rent Commencement Date. The Company has a one-time option to extend the term of the Lease for an additional 10 years, exercisable under certain conditions and at a market rate determined in accordance with the Burlington Lease. The annual base rent of the Burlington Lease is initially $57 per square foot per year, subject to annual increases of 2.5%. Monthly contractual payments are expected to range from $0.6 million to $0.8 million. Additionally, the Company is responsible for reimbursing the landlord for the Company’s share of the Premises’ property taxes and certain other operating expenses. The Burlington Lease also provides for a tenant improvement allowance from the landlord in an amount equal to $200 per square foot of the Premises, or approximately $24.4 million in total, following certain reductions to the tenant improvement allowance to account for the costs associated with changes to the landlord’s work on the Premises, as requested by the Company. The tenant improvement allowance will be used towards the design and construction of certain tenant improvements made to the Premises, subject to the terms set forth in the Burlington Lease. The Company is not involved in the initial construction of the core and shell of the building and will record the lease liability and right-of-use asset on its condensed consolidated balance sheet when the construction is substantially completed and it obtains control of the Premises, which is currently expected to be on or around the Commencement Date. In January 2022, in connection with the execution of the Burlington Lease, the Company issued a letter of credit collateralized by cash deposits of approximately $6.0 million. Subsequent to the execution of the Revolving Credit Agreement on July 29, 2022 (see Note 8, “Revolving Credit Agreement” for further details), the letter of credit is issued under the sub-facility limit of the Revolving Credit Agreement. Such letter of credit shall be reduced to approximately $4.2 million and $1.8 million at the conclusion of the third and sixth lease years, respectively, provided certain conditions set forth in the Burlington Lease are satisfied. For the three months ended March 31, 2023 and 2022, lease expense of less than $0.1 million was recorded related to short-term leases. For the three months ended March 31, 2023 and 2022, the Company recognized $1.7 million of operating lease expense. For the three months ended March 31, 2023 and 2022, the Company recognized less than $0.1 million of financing lease expense. Operating and finance lease assets and liabilities are as follows: (In thousands) Classification March 31, 2023 December 31, 2022 Assets Operating Right-of-use assets $ 40,851 $ 41,535 Finance Property and equipment, net 28 37 Total leased assets $ 40,879 $ 41,572 Liabilities Current Operating Current portion of operating lease liabilities $ 4,497 $ 4,302 Finance Other current liabilities 20 41 Non-current Operating Operating lease liabilities $ 42,365 $ 43,268 Total leased liabilities $ 46,882 $ 47,611
Leases	Leases The Company leases facilities in Ann Arbor, Michigan and Cambridge, Massachusetts. The Ann Arbor facility includes office space, and the Cambridge facilities include clean rooms, laboratories for MACI and Epicel manufacturing, and office space. The Company also leases offsite warehouse space, and other computer-related equipment. With respect to the Ann Arbor facility, in March 2023, the Company entered into an amendment to that lease extending its term until April 30, 2025. Monthly contractual payments are expected to range from $17,000 to $18,000. On January 28, 2022, the Company entered into a lease agreement (the “Burlington Lease”) to lease approximately 126,000 square feet of to-be-constructed manufacturing, laboratory and office space in Burlington, Massachusetts (the “Premises”). Once constructed, the Premises will serve as the Company’s new corporate headquarters and primary manufacturing facility. The term of the Burlington Lease is currently expected to begin mid-year 2023 (the “Commencement Date”). The Company’s obligation to pay rent for the Premises will begin on the earlier of: 13 months from the Commencement Date; or the date on which the Company first occupies the Premises to conduct operations (the “Rent Commencement Date”). The initial term of the Lease is 144 months following the Rent Commencement Date. The Company has a one-time option to extend the term of the Lease for an additional 10 years, exercisable under certain conditions and at a market rate determined in accordance with the Burlington Lease. The annual base rent of the Burlington Lease is initially $57 per square foot per year, subject to annual increases of 2.5%. Monthly contractual payments are expected to range from $0.6 million to $0.8 million. Additionally, the Company is responsible for reimbursing the landlord for the Company’s share of the Premises’ property taxes and certain other operating expenses. The Burlington Lease also provides for a tenant improvement allowance from the landlord in an amount equal to $200 per square foot of the Premises, or approximately $24.4 million in total, following certain reductions to the tenant improvement allowance to account for the costs associated with changes to the landlord’s work on the Premises, as requested by the Company. The tenant improvement allowance will be used towards the design and construction of certain tenant improvements made to the Premises, subject to the terms set forth in the Burlington Lease. The Company is not involved in the initial construction of the core and shell of the building and will record the lease liability and right-of-use asset on its condensed consolidated balance sheet when the construction is substantially completed and it obtains control of the Premises, which is currently expected to be on or around the Commencement Date. In January 2022, in connection with the execution of the Burlington Lease, the Company issued a letter of credit collateralized by cash deposits of approximately $6.0 million. Subsequent to the execution of the Revolving Credit Agreement on July 29, 2022 (see Note 8, “Revolving Credit Agreement” for further details), the letter of credit is issued under the sub-facility limit of the Revolving Credit Agreement. Such letter of credit shall be reduced to approximately $4.2 million and $1.8 million at the conclusion of the third and sixth lease years, respectively, provided certain conditions set forth in the Burlington Lease are satisfied. For the three months ended March 31, 2023 and 2022, lease expense of less than $0.1 million was recorded related to short-term leases. For the three months ended March 31, 2023 and 2022, the Company recognized $1.7 million of operating lease expense. For the three months ended March 31, 2023 and 2022, the Company recognized less than $0.1 million of financing lease expense. Operating and finance lease assets and liabilities are as follows: (In thousands) Classification March 31, 2023 December 31, 2022 Assets Operating Right-of-use assets $ 40,851 $ 41,535 Finance Property and equipment, net 28 37 Total leased assets $ 40,879 $ 41,572 Liabilities Current Operating Current portion of operating lease liabilities $ 4,497 $ 4,302 Finance Other current liabilities 20 41 Non-current Operating Operating lease liabilities $ 42,365 $ 43,268 Total leased liabilities $ 46,882 $ 47,611

Revolving Credit Agreement

Revolving Credit Agreement	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Revolving Credit Agreement	Revolving Credit Agreement On July 29, 2022, the Company, as borrower, entered into a $150.0 million five-year senior secured revolving credit agreement by and among the Company, the other loan parties thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as the administrative agent (the “Revolving Credit Agreement”). The Revolving Credit Agreement includes a $15.0 million sub-facility for the issuance of letters of credit, of which the Company is utilizing approximately $6.2 million. Amounts available under the Revolving Credit Agreement are for the working capital needs and other general corporate purposes of the Company. The Company incurred and capitalized approximately $1.1 million of debt issuance costs related to the Revolving Credit Agreement. Outstanding borrowings under the Revolving Credit Agreement bear interest, with pricing based from time to time at the Company’s election at (i) the Secured Overnight Financing Rate (“SOFR”) plus 0.10% plus a spread ranging from 1.25% to 2.50% as determined by the Company’s Total Net Leverage Ratio (as defined in the Revolving Credit Agreement) or (ii) the alternative base rate (as defined in the Revolving Credit Agreement) plus a spread ranging from 0.25% to 1.50% as determined by the Company’s Total Net Leverage Ratio. The Revolving Credit Agreement also includes a commitment fee, which ranges from 0.20% to 0.25% as determined by the Company’s Total Net Leverage Ratio. The Company is permitted to voluntarily prepay borrowings under the Revolving Credit Agreement, in whole or in part, without premium or penalty. On any business day on which the total amount of outstanding Revolving Loans (as defined in the Revolving Credit Agreement) and letters of credit exceeds the total Revolving Commitments (as defined in the Revolving Credit Agreement), the Company must prepay the Revolving Loans in an amount equal to such excess. As of March 31, 2023, there are no outstanding borrowings under the Revolving Credit Agreement. The Revolving Credit Agreement contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. The Revolving Credit Agreement requires the Company to be in quarterly compliance, measured on a trailing four quarter basis, with a financial covenant. The maximum Total Net Leverage Ratio (as defined in the Revolving Credit Agreement is 3.50 to 1.00. The Company may elect to increase the maximum Total Net Leverage Ratio to 4.00 to 1.00 for a period of four consecutive quarters in connection with a Permitted Acquisition (as defined in the Revolving Credit Agreement). The Revolving Credit Agreement contains usual and customary restrictions on the ability of the Company and its subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell or otherwise dispose of all, or substantially all, of its assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates. Obligations under the Revolving Credit Agreement are secured by first priority liens over substantially all of the assets of Vericel Corporation, excluding certain subsidiaries (subject to customary exclusions set forth in the Revolving Credit Agreement and the other transaction documents).

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The Vericel Corporation 2022 Omnibus Incentive Plan (“2022 Plan”) was approved on April 27, 2022, and provides incentives through the grant of stock options, stock appreciation rights, restricted stock awards and restricted stock units. The exercise price of stock options granted under the 2022 Plan shall not be less than the fair market value of the Company’s common stock on the date of grant. The 2022 Plan replaced the 1992 Stock Option Plan, the 2001 Stock Option Plan, the Amended and Restated 2004 Equity Incentive Plan, the 2009 Second Amended and Restated Omnibus Incentive Plan, the 2017 Omnibus Incentive Plan, and the Amended and Restated 2019 Omnibus Incentive Plan (“Prior Plans”), and no new grants have been granted under the Prior Plans after approval of the 2022 Plan. However, the expiration or forfeiture of options previously granted under the Prior Plans will increase the number of shares available for issuance under the 2022 Plan. Stock Compensation Expense Non-cash stock-based compensation expense (service-based stock options, restricted stock units and employee stock purchase plan) is summarized in the following table: Three Months Ended March 31, (in thousands) 2023 2022 Cost of product sales $ 885 $ 1,118 Research and development 977 1,350 Selling, general and administrative 6,869 7,063 Total non-cash stock-based compensation expense $ 8,731 $ 9,531 Service-Based Stock Options During the three months ended March 31, 2023 and 2022, the Company granted service-based options to purchase common stock of 467,957 and 993,589, respectively. The weighted-average grant-date fair value of service-based options granted during the three months ended March 31, 2023 and 2022 was $18.00 and $20.99 per option, respectively. Restricted Stock Units

Investments

Investments	3 Months Ended
	Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Investments	Investments Marketable debt securities held by the Company are classified as available-for-sale pursuant to ASC 320, Investments – Debt and Equity Securities , and carried at fair value in the accompanying condensed consolidated balance sheets on a settlement date basis. The following tables summarize the gross unrealized gains and losses of the Company’s marketable securities: March 31, 2023 Gross Unrealized Estimated Fair Value (In thousands) Amortized Cost Gains Losses Credit Losses Commercial paper $ 14,306 $ — $ (48) $ — $ 14,258 Corporate notes 43,157 — (559) — 42,598 U.S. government securities 4,920 5 — — 4,925 U.S. government agency bonds 15,600 — (29) — 15,571 $ 77,983 $ 5 $ (636) $ — $ 77,352 Classified as: Short-term investments $ 57,442 Long-term investments 19,910 $ 77,352 December 31, 2022 Gross Unrealized Estimated Fair Value (In thousands) Amortized Cost Gains Losses Credit Losses Commercial paper $ 15,707 $ — $ (101) $ — $ 15,606 Corporate notes 52,159 — (831) — 51,328 U.S. government agency bonds 21,545 — (46) — 21,499 $ 89,411 $ — $ (978) $ — $ 88,433 Classified as: Short-term investments $ 68,471 Long-term investments 19,962 $ 88,433 As of March 31, 2023 and December 31, 2022, all marketable securities held by the Company had remaining contractual maturities of three years or less. There have been no impairments of the Company’s assets measured and carried at fair value during the three months ended March 31, 2023 and 2022.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company’s fair value measurements are classified and disclosed in one of the following three categories: • Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; • Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; • Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The commercial paper, corporate notes, U.S. government securities, and U.S. government agency bonds are classified as Level 2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. There were no transfers into or out of Level 3 from December 31, 2022 to March 31, 2023. The following table summarizes the valuation of the Company’s financial instruments that are measured at fair value on a recurring basis: March 31, 2023 December 31, 2022 Fair value measurement category Fair value measurement category (In thousands) Total Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Assets: Money market funds $ 39,906 $ 39,906 $ — $ — $ 1,262 $ 1,262 $ — $ — Commercial paper 14,258 — 14,258 — 15,606 — 15,606 — Corporate notes 42,598 — 42,598 — 51,328 — 51,328 — U.S. government securities 4,925 — 4,925 — — — — — U.S. government agency bonds (a) 15,571 — 15,571 — 27,976 — 27,976 — $ 117,258 $ 39,906 $ 77,352 $ — $ 96,172 $ 1,262 $ 94,910 $ — (a) Approximately $6.5 million of U.S. government agency bonds had an original maturity of 90 days or less and were recorded as a cash equivalent as of December 31, 2022.

Net Loss Per Common Share

Net Loss Per Common Share	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Net Loss Per Common Share	Net Loss Per Common Share A summary of net loss per common share is presented below: Three Months Ended March 31, (Amounts in thousands, except per share amounts) 2023 2022 Net loss $ (7,495) $ (7,091) Basic weighted-average common shares outstanding 47,387 46,985 Effect of dilutive stock options and restricted stock units — — Diluted weighted-average common shares outstanding 47,387 46,985 Basic loss per common share $ (0.16) $ (0.15) Diluted loss per common share $ (0.16) $ (0.15) Anti-dilutive shares excluded from diluted net loss per common share: Stock options 6,918 6,479 Restricted stock units 954 625

NexoBrid License and Supply Agr

NexoBrid License and Supply Agreements	3 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
NexoBrid License and Supply Agreements	NexoBrid License and Supply Agreements On May 6, 2019, the Company entered into exclusive license and supply agreements with MediWound to commercialize NexoBrid in North America. NexoBrid is a topically-administered biological product, which was approved by the FDA on December 28, 2022 for commercial use in the U.S. NexoBrid contains proteolytic enzymes and is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns. Pursuant to the terms of the license agreement, following the FDA approval of NexoBrid, MediWound transferred the BLA to Vericel effective February 20, 2023. Both MediWound and Vericel, under the supervision of a Central Steering Committee comprised of members of both companies will continue to guide the development of NexoBrid in North America (the “Central Steering Committee”). NexoBrid is approved in the European Union (“EU”) and other international markets and has been designated as an orphan biologic in the U.S., EU and other international markets. In May 2019, the Company paid MediWound $17.5 million in consideration for the license, which was recorded as research and development expense during 2019. Pursuant to the terms of the license agreement, in February 2023, the Company tendered to MediWound a $7.5 million regulatory milestone payment following the FDA’s BLA approval of NexoBrid on December 28, 2022. The Company recorded the $7.5 million milestone payment for the licensing rights to commercially sell NexoBrid in the U.S., as an intangible asset (see Note 4, “Selected Balance Sheet Components” for further details). The Company is additionally obligated to pay MediWound up to $125.0 million, which is contingent upon meeting certain sales milestones. The first sales milestone payment of $7.5 million would be triggered when annual net sales of NexoBrid or improvements to it in North America exceed $75.0 million. As of March 31, 2023, the sales milestone payments are not yet probable and therefore, not recorded as a liability. The Company also will pay MediWound tiered royalties on net sales ranging from mid-high single-digit to mid-teen percentages, subject to customary reductions. Pursuant to the terms of the Company’s supply agreement with MediWound, MediWound will manufacture NexoBrid for the Company on a unit price basis, which may be increased pursuant to the terms of the supply agreement. MediWound is obligated to supply the Company with NexoBrid for sale in North America on an exclusive basis for the first five years of the term of the supply agreement. Under the supply agreement, the Company possesses the option to extend the initial term of the agreement by an additional 24 months, which it did in May 2022. After the exclusivity period or upon supply failure, the Company will be permitted to establish an alternate source of supply. Additionally, beginning in 2020 BARDA procured quantities of NexoBrid from MediWound for use as a medical countermeasure in the event of a mass casualty emergency in the U.S. involving thermal burns. The initial, quarterly, procurement of NexoBrid by BARDA under its agreement with MediWound completed during the third quarter of 2022. As a part of BARDA’s commitment to procure NexoBrid, the Company has received a percentage of gross profit for sales directly to BARDA. As of March 31, 2023, the Company did not hold a direct contract or distribution agreement with BARDA, or take title to the product procured by BARDA. On May 9, 2023, MediWound announced BARDA’s award of additional funding under the parties’ existing agreement, $3 million of which will support the replacement of NexoBrid, previously procured for emergency response preparedness, which has since expired. Pursuant to the terms of the Company’s license agreement with MediWound, the Company would recognize revenue based on a percentage of gross profits, minus a percentage of net sales, on any sales of NexoBrid directly to BARDA, upon delivery, pursuant to this additional award.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies From time to time, the Company could be a party to various legal proceedings arising in the ordinary course of business. The costs and outcome of litigation, regulatory, investigatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. If a matter is both probable to result in material liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible material loss or range of loss. If such loss is not probable or cannot be reasonably estimated, a liability is not recorded in its condensed consolidated financial statements. As of March 31, 2023, the Company has no material ongoing litigation in which the Company was a party or any material ongoing regulatory or other proceedings and had no knowledge of any investigations by government or regulatory authorities in which the Company is a target that could have a material adverse effect on its current business.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events In April 2023, in connection with the Burlington Lease, the Company entered into a construction escrow agreement (the “Construction Escrow Agreement”) with the facility’s landlord and an escrow agent. Pursuant to the terms of the Construction Escrow Agreement, in April 2023, the Company began funding into an escrow account maintained by the escrow agent a portion of its share of tenant improvement construction costs at the facility, which will be designated as restricted cash. At the same time, the facility’s landlord began funding a portion of its tenant improvement allowance through a separate escrow account. To date, the Company has transferred into its escrow account 50% of its required cost amount, or approximately $28.3 million. The Company anticipates funding the remaining 50% of its required cost amount in late 2023 or early 2024. Additionally, and in order to support the expansion of the Company’s autologous cell manufacturing operations at the new facility in Burlington, the Company plans to invest in the acquisition and installation of certain specialized manufacturing and laboratory equipment.

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and investments in marketable debt securities. The Company may maintain deposits in financial institutions in excess of the insurance coverage offered by the Federal Deposit Insurance Corporation (“FDIC”), the loss of which could have a negative effect on our operations and liquidity. The Company is closely monitoring ongoing events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally. The Company believes that it is not exposed to significant credit risk as its deposits, including cash and cash equivalents, are held at multiple high credit quality financial institutions. The Company has not experienced any losses on these deposits; however no assurances can be provided that there will not be losses experienced in the future. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated based on the fact that many of these securities are either government-backed or of high credit rating.
Recent Accounting Pronouncements	Recent Accounting Pronouncements No new accounting standards were adopted during the three months ended March 31, 2023. The Company considers the applicability and impact of any recent Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). Based on the assessment, the ASUs were determined to be either not applicable or are expected to have minimal impact on the Company’s condensed consolidated financial statements.

Revenue (Tables)

Revenue (Tables)	3 Months Ended
	Mar. 31, 2023
Risks and Uncertainties [Abstract]
Schedule of disaggregation of revenue	The following table and descriptions below show the products from which the Company generated its revenue for the periods indicated: Three Months Ended March 31, Revenue by product (in thousands) 2023 2022 MACI implants and kits Implants based on contracted rate sold through a specialty pharmacy (a) $ 22,698 $ 15,190 Implants subject to third party reimbursement sold through a specialty pharmacy (b) 3,485 3,369 Implants sold direct based on contracted rates (c) 6,919 5,634 Implants sold direct subject to third-party reimbursement (d) 501 861 Biopsy kits - direct bill 535 522 Change in estimates related to prior periods (e) 52 419 Total MACI implants and kits 34,190 25,995 Epicel Direct bill (hospital) 6,827 9,857 NexoBrid revenue (f) — 222 Total revenue $ 41,017 $ 36,074 (a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts. (b) Represents implants sold through Orsini and AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer, and are subject to third-party reimbursement. The amount of reimbursement is established based on publicly available rates, fee schedules or past payer precedents. (c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS. (d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider. (e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare and relate to changes to the initial expected reimbursement or collection expectations upon completion of the billing claims process. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period. (f) Represents revenue based on a percentage of gross profits for sales of NexoBrid to BARDA, pursuant to the license agreement between the Company and MediWound (see Note 11).

Selected Balance Sheet Compon_2

Selected Balance Sheet Components (Tables)	3 Months Ended
	Mar. 31, 2023
Balance Sheet Related Disclosures [Abstract]
Schedule of inventory	Inventory consisted of the following: (In thousands) March 31, 2023 December 31, 2022 Raw materials $ 14,264 $ 15,101 Work-in-process 1,043 832 Finished goods 63 53 Total inventory $ 15,370 $ 15,986
Schedule of property and equipment, net	Property and Equipment, net consisted of the following: (In thousands) March 31, 2023 December 31, 2022 Machinery and equipment $ 5,212 $ 5,041 Furniture, fixtures and office equipment 1,710 1,710 Computer equipment and software 8,208 8,224 Leasehold improvements 14,120 13,689 Construction in process 8,121 5,438 Financing right-of-use lease 28 37 Total property and equipment, gross 37,399 34,139 Less accumulated depreciation (19,202) (18,302) Total property and equipment, net $ 18,197 $ 15,837
Schedule of finite-lived intangible assets	Intangible assets, net consisted of the following: March 31, 2023 December 31, 2022 (In thousands) Useful Live (in years) Amortization Method Cost Accumulated Amortization Net Cost Accumulated Amortization Net NexoBrid license 12 Straight-line $ 7,500 $ (156) $ 7,344 $ 7,500 $ — $ 7,500
Schedule of finite-lived intangible assets, future amortization expense	Future amortization expense of intangible assets as of March 31, 2023 is estimated to be as follows: (In thousands) Amount Remainder of 2023 $ 469 2024 625 2025 625 2026 625 2027 625 Thereafter 4,375 Total $ 7,344
Schedule of accrued expenses	Accrued Expenses consisted of the following: (In thousands) March 31, 2023 December 31, 2022 Bonus related compensation $ 3,588 $ 7,132 Employee related accruals 2,739 3,101 Insurance reimbursement-related liabilities 5,769 5,030 Other accrued expenses 1,015 927 Total accrued expenses $ 13,111 $ 16,190

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Schedule of assets and liabilities	Operating and finance lease assets and liabilities are as follows: (In thousands) Classification March 31, 2023 December 31, 2022 Assets Operating Right-of-use assets $ 40,851 $ 41,535 Finance Property and equipment, net 28 37 Total leased assets $ 40,879 $ 41,572 Liabilities Current Operating Current portion of operating lease liabilities $ 4,497 $ 4,302 Finance Other current liabilities 20 41 Non-current Operating Operating lease liabilities $ 42,365 $ 43,268 Total leased liabilities $ 46,882 $ 47,611

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of non-cash stock-based compensation expense	Non-cash stock-based compensation expense (service-based stock options, restricted stock units and employee stock purchase plan) is summarized in the following table: Three Months Ended March 31, (in thousands) 2023 2022 Cost of product sales $ 885 $ 1,118 Research and development 977 1,350 Selling, general and administrative 6,869 7,063 Total non-cash stock-based compensation expense $ 8,731 $ 9,531

Investments (Tables)

Investments (Tables)	3 Months Ended
	Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Schedule of fair value of securities, not including cash	The following tables summarize the gross unrealized gains and losses of the Company’s marketable securities: March 31, 2023 Gross Unrealized Estimated Fair Value (In thousands) Amortized Cost Gains Losses Credit Losses Commercial paper $ 14,306 $ — $ (48) $ — $ 14,258 Corporate notes 43,157 — (559) — 42,598 U.S. government securities 4,920 5 — — 4,925 U.S. government agency bonds 15,600 — (29) — 15,571 $ 77,983 $ 5 $ (636) $ — $ 77,352 Classified as: Short-term investments $ 57,442 Long-term investments 19,910 $ 77,352 December 31, 2022 Gross Unrealized Estimated Fair Value (In thousands) Amortized Cost Gains Losses Credit Losses Commercial paper $ 15,707 $ — $ (101) $ — $ 15,606 Corporate notes 52,159 — (831) — 51,328 U.S. government agency bonds 21,545 — (46) — 21,499 $ 89,411 $ — $ (978) $ — $ 88,433 Classified as: Short-term investments $ 68,471 Long-term investments 19,962 $ 88,433

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of valuation of the company's investments and financial instruments that are measured at fair value on a recurring basis	The following table summarizes the valuation of the Company’s financial instruments that are measured at fair value on a recurring basis: March 31, 2023 December 31, 2022 Fair value measurement category Fair value measurement category (In thousands) Total Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Assets: Money market funds $ 39,906 $ 39,906 $ — $ — $ 1,262 $ 1,262 $ — $ — Commercial paper 14,258 — 14,258 — 15,606 — 15,606 — Corporate notes 42,598 — 42,598 — 51,328 — 51,328 — U.S. government securities 4,925 — 4,925 — — — — — U.S. government agency bonds (a) 15,571 — 15,571 — 27,976 — 27,976 — $ 117,258 $ 39,906 $ 77,352 $ — $ 96,172 $ 1,262 $ 94,910 $ — (a) Approximately $6.5 million of U.S. government agency bonds had an original maturity of 90 days or less and were recorded as a cash equivalent as of December 31, 2022.

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Schedule of net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two class method	A summary of net loss per common share is presented below: Three Months Ended March 31, (Amounts in thousands, except per share amounts) 2023 2022 Net loss $ (7,495) $ (7,091) Basic weighted-average common shares outstanding 47,387 46,985 Effect of dilutive stock options and restricted stock units — — Diluted weighted-average common shares outstanding 47,387 46,985 Basic loss per common share $ (0.16) $ (0.15) Diluted loss per common share $ (0.16) $ (0.15) Anti-dilutive shares excluded from diluted net loss per common share: Stock options 6,918 6,479 Restricted stock units 954 625

Organization (Details)

Organization (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) segment product	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of commercial-stage products | product	3
Number of reportable segments | segment	1
Accumulated deficit	$ 407,490		$ 399,995
Net loss	7,495	$ 7,091
Cash and cash equivalents	61,834	$ 55,659	$ 51,067
Short term investments	$ 77,400

Revenue - Narrative (Details)

Revenue - Narrative (Details) $ in Millions		3 Months Ended
	May 09, 2023 USD ($)	Mar. 31, 2023 USD ($) pharmacy	Dec. 31, 2022 USD ($)
Disaggregation of Revenue [Line Items]
Number of specialty pharmacies | pharmacy		2
Allowance for doubtful accounts		$ 7.1	$ 6.1
Change in estimate of uncollectible (percent)		0.50%
Change in revenue recognized due to 0.5% change in uncollectible percentage		$ 0.3
MediWound Ltd | Subsequent event
Disaggregation of Revenue [Line Items]
Additional funding	$ 3

Revenue - Summary of Disaggrega

Revenue - Summary of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Product sales, net	$ 41,017	$ 35,852
NexoBrid revenue	0	222
Total revenue	41,017	36,074
Accounting Standards Update 2014-09 | Change in estimates related to prior periods
Disaggregation of Revenue [Line Items]
Product sales, net	52	419
M A C I Implants and kits
Disaggregation of Revenue [Line Items]
Product sales, net	34,190	25,995
Through Intermediary | MACI implants and kits | Contract rate
Disaggregation of Revenue [Line Items]
Product sales, net	22,698	15,190
Through Intermediary | MACI implants and kits | Time-and-materials contract
Disaggregation of Revenue [Line Items]
Product sales, net	3,485	3,369
Time-and-materials contract | MACI implants and kits | Time-and-materials contract
Disaggregation of Revenue [Line Items]
Product sales, net	501	861
Provider or Facility | MACI implants and kits | Contract rate
Disaggregation of Revenue [Line Items]
Product sales, net	6,919	5,634
Provider or Facility | NexoBrid
Disaggregation of Revenue [Line Items]
NexoBrid revenue	0	222
Directly to consumer | Biopsy kits
Disaggregation of Revenue [Line Items]
Product sales, net	535	522
Directly to consumer | Epicel
Disaggregation of Revenue [Line Items]
Product sales, net	$ 6,827	$ 9,857

Selected Balance Sheet Compon_3

Selected Balance Sheet Components - Summary of inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Inventory:
Raw materials	$ 14,264	$ 15,101
Work-in-process	1,043	832
Finished goods	63	53
Total inventory	$ 15,370	$ 15,986

Selected Balance Sheet Compon_4

Selected Balance Sheet Components - Schedule of property and equipment, net (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property and equipment, net:
Financing right-of-use lease	$ 28	$ 37
Total property and equipment, gross	37,399	34,139
Less accumulated depreciation	(19,202)	(18,302)
Total property and equipment, net	18,197	15,837
Machinery and equipment
Property and equipment, net:
Total property and equipment, gross	5,212	5,041
Furniture, fixtures and office equipment
Property and equipment, net:
Total property and equipment, gross	1,710	1,710
Computer equipment and software
Property and equipment, net:
Total property and equipment, gross	8,208	8,224
Leasehold improvements
Property and equipment, net:
Total property and equipment, gross	14,120	13,689
Construction in process
Property and equipment, net:
Total property and equipment, gross	$ 8,121	$ 5,438

Selected Balance Sheet Compon_5

Selected Balance Sheet Components - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Property, Plant and Equipment [Line Items]
Depreciation	$ 1	$ 0.9
Licensing Agreements
Property, Plant and Equipment [Line Items]
Amortization of intangible assets	$ 0.2

Selected Balance Sheet Compon_6

Selected Balance Sheet Components -Schedule of finite-lived intangible assets (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Total	$ 7,344	$ 7,500
Licensing Agreements
Property, Plant and Equipment [Line Items]
Useful Live (in years)	12 years	12 years
Cost	$ 7,500	$ 7,500
Accumulated Amortization	(156)	0
Total	$ 7,344	$ 7,500

Selected Balance Sheet Compon_7

Selected Balance Sheet Components -Schedule of finite-lived intangible assets, future amortization expense (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Total	$ 7,344	$ 7,500
Licensing Agreements
Finite-Lived Intangible Assets [Line Items]
Remainder of 2023	469
2024	625
2025	625
2026	625
2027	625
Thereafter	4,375
Total	$ 7,344	$ 7,500

Selected Balance Sheet Compon_8

Selected Balance Sheet Components - Schedule of accrued expenses (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Accrued expenses
Bonus related compensation	$ 3,588	$ 7,132
Employee related accruals	2,739	3,101
Insurance reimbursement-related liabilities	5,769	5,030
Other accrued expenses	1,015	927
Total accrued expenses	$ 13,111	$ 16,190

Leases - Narrative (Details)

Leases - Narrative (Details) ft² in Thousands, $ in Thousands		1 Months Ended	3 Months Ended
	Jan. 28, 2022 USD ($) ft² $ / ft² renewal_option	Jan. 31, 2022 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)
Lessee, Lease, Description [Line Items]
Short-term lease costs (less than)			$ 100	$ 100
Operating lease expense			1,700	1,700
Finance lease expense (less than)			100	$ 100
25 Network Drive, Burlington, Massachusetts
Lessee, Lease, Description [Line Items]
Area of real estate property | ft²	126
Rent start date, term	13 months
Term of contract	144 months
Number of renewal options | renewal_option	1
Lease option to extend term	10 years
Annual lease per square foot | $ / ft²	57
Annual lease base rent square subject to increase percentage	2.50%
Tenant improvement allowance per square foot | $ / ft²	200
Tenant improvement allowance	$ 24,400
Letter of credit cash deposit		$ 6,000
Letter of credit cash deposit lease year three		4,200
Letter of credit cash deposit lease year six		$ 1,800
Minimum | 25 Network Drive, Burlington, Massachusetts
Lessee, Lease, Description [Line Items]
Monthly contractual lease payments	600
Minimum | Ann Arbor Michigan
Lessee, Lease, Description [Line Items]
Monthly contractual lease payments			17
Maximum | 25 Network Drive, Burlington, Massachusetts
Lessee, Lease, Description [Line Items]
Monthly contractual lease payments	$ 800
Maximum | Ann Arbor Michigan
Lessee, Lease, Description [Line Items]
Monthly contractual lease payments			$ 18

Leases - Summary of assets and

Leases - Summary of assets and liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Assets
Operating	$ 40,851	$ 41,535
Finance	28	37
Total leased assets	40,879	41,572
Current
Operating	4,497	4,302
Finance	20	41
Non-current
Operating	42,365	43,268
Total leased liabilities	$ 46,882	$ 47,611
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Property and equipment, net	Property and equipment, net
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other current liabilities	Other current liabilities

Revolving Credit Agreement (Det

Revolving Credit Agreement (Details) - Line of credit	Jul. 29, 2022 USD ($)	Mar. 31, 2023 USD ($)
Debt Instrument [Line Items]
Issuance of letters of credit	$ 6,200,000
Revolving credit facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 150,000,000
Debt instrument, term	5 years
Debt issuance costs, net	$ 1,100,000
Outstanding borrowings		$ 0
Leverage ratio	3.50
Increase option for leverage ratio	4
Revolving credit facility | Minimum
Debt Instrument [Line Items]
Line of credit facility, commitment fee (in percent)	0.20%
Revolving credit facility | Maximum
Debt Instrument [Line Items]
Line of credit facility, commitment fee (in percent)	0.25%
Revolving credit facility | SOFR
Debt Instrument [Line Items]
Basis spread on variable rate (in percent)	0.10%
Revolving credit facility | SOFR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate (in percent)	1.25%
Revolving credit facility | SOFR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate (in percent)	2.50%
Revolving credit facility | Base rate | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate (in percent)	0.25%
Revolving credit facility | Base rate | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate (in percent)	1.50%
Letter of credit
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 15,000,000

Stock-Based Compensation - Expe

Stock-Based Compensation - Expense (Details) - Employee stock purchase plan and service-based stock options - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total non-cash stock-based compensation expense	$ 8,731	$ 9,531
Cost of product sales
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total non-cash stock-based compensation expense	885	1,118
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total non-cash stock-based compensation expense	977	1,350
Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total non-cash stock-based compensation expense	$ 6,869	$ 7,063

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stock options
Stock-Based Compensation
Granted (in shares)	467,957	993,589
Weighted average grant-date fair value (in dollars per share)	$ 18	$ 20.99
Restricted stock units
Stock-Based Compensation
Restricted stock units granted (shares)	496,505	343,022
Weighted-average grant date fair value (in dollars per share)	$ 29.82	$ 34.97

Investments (Details)

Investments (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Marketable Securities [Line Items]
Amortized Cost	$ 77,983,000		$ 89,411,000
Gains	5,000		0
Losses	(636,000)		(978,000)
Credit Losses	0		0
Estimated Fair Value	$ 77,352,000		$ 88,433,000
Remaining contractual maturity period	3 years		3 years
Impairments of assets	$ 0	$ 0
Short-term investments
Marketable Securities [Line Items]
Estimated Fair Value	57,442,000		$ 68,471,000
Long-term investments
Marketable Securities [Line Items]
Estimated Fair Value	19,910,000		19,962,000
Commercial paper
Marketable Securities [Line Items]
Amortized Cost	14,306,000		15,707,000
Gains	0		0
Losses	(48,000)		(101,000)
Credit Losses	0		0
Estimated Fair Value	14,258,000		15,606,000
Corporate notes
Marketable Securities [Line Items]
Amortized Cost	43,157,000		52,159,000
Gains	0		0
Losses	(559,000)		(831,000)
Credit Losses	0		0
Estimated Fair Value	42,598,000		51,328,000
U.S. government securities
Marketable Securities [Line Items]
Amortized Cost	4,920,000
Gains	5,000
Losses	0
Credit Losses	0
Estimated Fair Value	4,925,000
U.S. government agency bonds
Marketable Securities [Line Items]
Amortized Cost	15,600,000		21,545,000
Gains	0		0
Losses	(29,000)		(46,000)
Credit Losses	0		0
Estimated Fair Value	$ 15,571,000		$ 21,499,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Liabilities that are measured at fair value on a recurring basis
Debt securities, fair value	$ 77,352	$ 88,433
U.S. government securities
Liabilities that are measured at fair value on a recurring basis
Debt securities, fair value	4,925
U.S. government agency bonds
Liabilities that are measured at fair value on a recurring basis
Debt securities, fair value	15,571	21,499
Recurring
Liabilities that are measured at fair value on a recurring basis
Assets, fair value	117,258	96,172
Recurring | Level 1
Liabilities that are measured at fair value on a recurring basis
Assets, fair value	39,906	1,262
Recurring | Level 2
Liabilities that are measured at fair value on a recurring basis
Assets, fair value	77,352	94,910
Recurring | Level 3
Liabilities that are measured at fair value on a recurring basis
Assets, fair value	0	0
Recurring | Commercial paper
Liabilities that are measured at fair value on a recurring basis
Debt securities, fair value	14,258	15,606
Recurring | Commercial paper | Level 1
Liabilities that are measured at fair value on a recurring basis
Debt securities, fair value	0	0
Recurring | Commercial paper | Level 2
Liabilities that are measured at fair value on a recurring basis
Debt securities, fair value	14,258	15,606
Recurring | Commercial paper | Level 3
Liabilities that are measured at fair value on a recurring basis
Debt securities, fair value	0	0
Recurring | Corporate notes
Liabilities that are measured at fair value on a recurring basis
Debt securities, fair value	42,598	51,328
Recurring | Corporate notes | Level 1
Liabilities that are measured at fair value on a recurring basis
Debt securities, fair value	0	0
Recurring | Corporate notes | Level 2
Liabilities that are measured at fair value on a recurring basis
Debt securities, fair value	42,598	51,328
Recurring | Corporate notes | Level 3
Liabilities that are measured at fair value on a recurring basis
Debt securities, fair value	0	0
Recurring | U.S. government securities
Liabilities that are measured at fair value on a recurring basis
Debt securities, fair value	4,925	0
Recurring | U.S. government securities | Level 1
Liabilities that are measured at fair value on a recurring basis
Debt securities, fair value	0	0
Recurring | U.S. government securities | Level 2
Liabilities that are measured at fair value on a recurring basis
Debt securities, fair value	4,925	0
Recurring | U.S. government securities | Level 3
Liabilities that are measured at fair value on a recurring basis
Debt securities, fair value	0	0
Recurring | U.S. government agency bonds
Liabilities that are measured at fair value on a recurring basis
Debt securities, fair value	15,571	27,976
Recurring | U.S. government agency bonds | Cash and cash equivalents
Liabilities that are measured at fair value on a recurring basis
Debt securities, fair value		6,500
Recurring | U.S. government agency bonds | Level 1
Liabilities that are measured at fair value on a recurring basis
Debt securities, fair value	0	0
Recurring | U.S. government agency bonds | Level 2
Liabilities that are measured at fair value on a recurring basis
Debt securities, fair value	15,571	27,976
Recurring | U.S. government agency bonds | Level 3
Liabilities that are measured at fair value on a recurring basis
Debt securities, fair value	0	0
Recurring | Money market funds
Liabilities that are measured at fair value on a recurring basis
Money market funds	39,906	1,262
Recurring | Money market funds | Level 1
Liabilities that are measured at fair value on a recurring basis
Money market funds	39,906	1,262
Recurring | Money market funds | Level 2
Liabilities that are measured at fair value on a recurring basis
Money market funds	0	0
Recurring | Money market funds | Level 3
Liabilities that are measured at fair value on a recurring basis
Money market funds	$ 0	$ 0

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Net Income (Loss) Attributable to Parent [Abstract]
Net loss	$ (7,495)	$ (7,091)
Basic weighted-average common shares outstanding (in shares)	47,387	46,985
Effect of dilutive stock options and restricted stock units (in shares)	0	0
Diluted weighted-average common shares outstanding (in shares)	47,387	46,985
Basic loss per common share (in USD per share)	$ (0.16)	$ (0.15)
Diluted loss per common share (in USD per share)	$ (0.16)	$ (0.15)
Stock options
Anti-dilutive shares excluded from diluted net loss per common share:
Anti-dilutive shares excluded from the calculation of diluted earnings per share (in shares)	6,918	6,479
Restricted stock units
Anti-dilutive shares excluded from diluted net loss per common share:
Anti-dilutive shares excluded from the calculation of diluted earnings per share (in shares)	954	625

NexoBrid License and Supply A_2

NexoBrid License and Supply Agreements (Details) - MediWound Ltd - USD ($) $ in Millions		1 Months Ended
	May 09, 2023	May 31, 2019	Feb. 28, 2023
Related Party Transaction [Line Items]
Consideration payment for license		$ 17.5
Contingent consideration		7.5	$ 7.5
Maximum contingent consideration		125
Sales threshold for first milestone		$ 75
Term of supply agreement		5 years
Renewal term of supply agreement		24 months
Subsequent event
Related Party Transaction [Line Items]
Additional funding	$ 3

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent event - 25 Network Drive, Burlington, Massachusetts $ in Millions	Apr. 30, 2023 USD ($)
Subsequent Event [Line Items]
Percent contributed to escrow account	50%
Escrow deposit amount	$ 28.3
Remaining percent to be contributed to escrow account	50%